These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 6404817)

  • 41. Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on gram-negative bacterial sepsis in burned mice.
    Fomsgaard A; Holder IA
    APMIS; 1993 Mar; 101(3):229-34. PubMed ID: 8507460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.
    Yang F; Gu J; Yang L; Gao C; Jing H; Wang Y; Zeng H; Zou Q; Lv F; Zhang J
    Sci Rep; 2017 Jun; 7(1):3957. PubMed ID: 28638106
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Broad-spectra human monoclonal antibodies that protect mice infected with Pseudomonas aeruginosa.
    Noguchi H; Yokota S; Ohtsuka H; Kohzuki T; Terashima M; Irie K
    Antibiot Chemother (1971); 1991; 44():172-84. PubMed ID: 1724892
    [No Abstract]   [Full Text] [Related]  

  • 44. Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Que JO; Cross AS; Fürer E
    Vaccine; 1995 Apr; 13(5):449-53. PubMed ID: 7639013
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protection against exotoxin A (ETA) and Pseudomonas aeruginosa infection in mice with ETA-specific antipeptide antibodies.
    El-Zaim HS; Chopra AK; Peterson JW; Vasil ML; Heggers JP
    Infect Immun; 1998 Nov; 66(11):5551-4. PubMed ID: 9784572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The contribution of exoproducts to virulence of Pseudomonas aeruginosa.
    Nicas TI; Iglewski BH
    Can J Microbiol; 1985 Apr; 31(4):387-92. PubMed ID: 2988728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antigens of Pseudomonas aeruginosa and their use in immunoprophylaxis and immunotherapy.
    Stanislavsky ES; Dmitriev BA; Lányi B; Joó I
    Acta Microbiol Hung; 1985; 32(1):3-37. PubMed ID: 2412389
    [No Abstract]   [Full Text] [Related]  

  • 48. Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model.
    Gilleland HE; Gilleland LB; Fowler MR
    J Med Microbiol; 1993 Feb; 38(2):79-86. PubMed ID: 8429543
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pseudomonas aeruginosa antibody detection in cystic fibrosis patients.
    Trancassini M; De Vito D; Quattrucci S; Cipriani P
    New Microbiol; 1999 Apr; 22(2):85-9. PubMed ID: 10322606
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Flagellin and pilin immunization against multi-drug resistant Pseudomonas aeruginosa protects mice in the burn wound sepsis model.
    Korpi F; Hashemi FB; Irajian G; Fatemi MJ; Laghaei P; Behrouz B
    Immunol Lett; 2016 Aug; 176():8-17. PubMed ID: 27210422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model.
    Barnea Y; Carmeli Y; Gur E; Kuzmenko B; Gat A; Neville LF; Eren R; Dagan S; Navon-Venezia S
    Plast Reconstr Surg; 2006 Jun; 117(7):2284-91. PubMed ID: 16772930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clearance of Pseudomonas aeruginosa from normal rat lungs after immunization with somatic antigens or toxin A.
    Johansen HK; Cryz SJ; Høiby N
    APMIS; 1994 Jul; 102(7):545-53. PubMed ID: 7917224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relation between antibody response to Pseudomonas aeruginosa exoproteins and colonization/infection in patients with cystic fibrosis.
    Granström M; Ericsson A; Strandvik B; Wretlind B; Pavlovskis OR; Berka R; Vasil ML
    Acta Paediatr Scand; 1984 Nov; 73(6):772-7. PubMed ID: 6441448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.
    Cryz SJ; Cross AS; Sadoff JC; Fürer E
    Infect Immun; 1990 Feb; 58(2):373-7. PubMed ID: 2105272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reaction of antibody in sera from cystic fibrosis patients with non-toxic forms of Pseudomonas aeruginosa exotoxin A.
    Klinger KW; Shuster CW; Klinger J
    Eur J Clin Microbiol; 1985 Apr; 4(2):201-6. PubMed ID: 3924609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.
    Cryz SJ; Fürer E; Que JU
    Infect Immun; 1991 Jan; 59(1):45-50. PubMed ID: 1898901
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant protein composed of Pseudomonas exotoxin A, outer membrane proteins I and F as vaccine against P. aeruginosa infection.
    Chen TY; Shang HF; Chen TL; Lin CP; Hui CF; Hwang J
    Appl Microbiol Biotechnol; 1999 Oct; 52(4):524-33. PubMed ID: 10570800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-lipopolysaccharide antibody levels in patients with AIDS at the onset of Pseudomonas aeruginosa bacteremia.
    Kumar PN; Collins MS; Pierce PF
    J Acquir Immune Defic Syndr (1988); 1994 Jun; 7(6):587-91. PubMed ID: 8176642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice.
    Holder IA; Neely AN; Frank DW
    Infect Immun; 2001 Sep; 69(9):5908-10. PubMed ID: 11500471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
    Kaloshin AA; Isakov MA; Mikhailova NA; Vertiev JV
    Bull Exp Biol Med; 2013 Jan; 154(3):346-50. PubMed ID: 23484197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.